temozolomide Archives - Double Bond Pharmaceutical

Local chemotherapy in treatment of brain tumors. Part 2. Efficiency of treatment of patients with neuroepithelial brain tumors secondary to intraoperative local chemotherapy

By gustav|2025-02-19T00:34:43+01:00February 19th, 2025|

According to the results of open, controlled, retro prospective, comparative, randomized clinical trial found an increase in the efficacy of the combined treatment of malignant brain tumors in the application of intraoperative local chemotherapy drug (LHT) temodex. In particular, the median survival of patients with Grade III–IV tumors in the supratentorial localization background [...]

Local chemotherapy in treatment of brain tumors. Part 1. Characteristics of neurosurgical intervention and the course of the postoperative period in patients with brain tumors secondary to local chemotherapy

By gustav|2025-02-19T00:20:22+01:00February 19th, 2025|

The assessment of the clinical progression of the postoperative period in patients with neuroepithelial brain tumors when using intraoperative local chemotherapy (iLCT) with Temodex, which is an anticancer medicinal product of the active substance of temozolomide immobilized on highly substituted dextran phosphate. Clinical manifestations and features of the early postoperative period were analyzed depending [...]

Local delivery of temozolomide via a biologically inert carrier (Temodex)

By gustav|2025-02-05T22:54:38+01:00February 5th, 2025|

Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are [...]

Double Bond aims at adaptive design for SI-053 Phase I

By gustav|2018-11-20T23:39:15+01:00November 19th, 2018|

Double Bond aims at adaptive design for SI-053 Phase I FRI, MAY 04, 2018 10:19 CET Double Bond Pharmaceutical (DBP) has signed a service contract with Cytel Inc, a leading provider of clinical research services and software, to develop an adaptive model-based study design for [...]